LPL Financial’s Pasithea Therapeutics KTTA Stock Holding History

LPL Financial’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$7.21K	–	5905
2025 Q2	$7.21K	Buy	+10,000	New	+$10.9K	﹤0.01%	5533

Other funds holding KTTA

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LPL Financial's KTTA Position: Q3 2025 in Review

LPL Financial sold out of Pasithea Therapeutics (KTTA) in Q3 2025, closing a stake of 10,000 shares — an estimated $7.21K sold.

LPL Financial first reported a position in KTTA in Q2 2025 and held it in 1 quarter. The position peaked at $7.21K in Q2 2025. 19 funds tracked by Wall St. Rank hold KTTA as of Q3 2025.

LPL Financial reported no remaining Pasithea Therapeutics position as of Q3 2025 after selling out during the quarter.
LPL Financial sold 10,000 Pasithea Therapeutics shares in Q3 2025, an estimated $7.21K.
LPL Financial first reported a position in Pasithea Therapeutics in Q2 2025 and held it in 1 quarter.
LPL Financial's Pasithea Therapeutics position peaked at $7.21K in Q2 2025.
19 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2025.

Based on LPL Financial's 13F filing for Q3 2025, filed 12 Nov 2025.